The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL938     (2S)-2-[[(2S)-1-[(2S)-2- [[(2S)-2-[[(2S)-2...

Synonyms: CHEBI:187771, FT-0630581, CAS-34273-10-4, AC1O44IX, Tox21_112332, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Saralasin


Psychiatry related information on Saralasin


High impact information on Saralasin


Chemical compound and disease context of Saralasin


Biological context of Saralasin


Anatomical context of Saralasin

  • Renal vein norepinephrine efflux during RNS was disproportionately increased in NE-ARF (P less than 0.001) and was suppressed by saralasin + SQ29548 infusion (P less than 0.005) [16].
  • In contrast, saralasin decreased blood flow to the mucosa (-28%; P less than 0.001) and increased blood flow to the muscularis (+140%; P less than 0.001) of the colon under basal conditions and also reduced the hypotension-induced vasoconstriction of the colonic muscularis (P less than 0.01) [17].
  • Many of the effects of saralasin and of converting-enzyme inhibitor on blood-pressure in relation to concentrations of renin in blood plasma and in the kidneys seem to support this hypothesis [20].
  • In contrast, saralasin "response" occurred in more than 80% of patients with renal artery stenosis and lateralizing functional studies and 100% of cases of "proven" renovascular hypertension (cure or improvement of hypertension after operative treatment) [21].
  • ANF was reduced in both atria of saralasin-resistant 2K1C animals but only in the left atrium of the sensitive group [19].

Associations of Saralasin with other chemical compounds


Gene context of Saralasin


Analytical, diagnostic and therapeutic context of Saralasin


  1. Pressor response to saralasin reversed by phentolamine in essential hypertension. Takishita, S., Fukiyama, K., Tamaki, K., Omae, T. N. Engl. J. Med. (1978) [Pubmed]
  2. Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man. Pettinger, W.A., Mitchell, H.C. N. Engl. J. Med. (1975) [Pubmed]
  3. Depressor effect of saralasin in hypertensive crisis due to pheochromocytoma. Röckel, A., Heidland, A., Appel, E., Palm, D. N. Engl. J. Med. (1977) [Pubmed]
  4. Systemic circulatory adjustments to acute hypoxia and reoxygenation in unanesthetized sheep. Role of renin, angiotensin II, and catecholamine interactions. Davidson, D., Stalcup, S.A. J. Clin. Invest. (1984) [Pubmed]
  5. Altered renin release and propranolol potentiation of vasodilatory drug hypotension. Pettinger, W.A., Keeton, K. J. Clin. Invest. (1975) [Pubmed]
  6. Some central mechanisms of thirst in the dog. Ramsay, D.J., Reid, I.A. J. Physiol. (Lond.) (1975) [Pubmed]
  7. Effect of angiotensin II and saralasin on motor activity and the passive avoidance behavior of rats. Braszko, J.J., Wiśniewski, K. Peptides (1988) [Pubmed]
  8. Role of the renin-angiotensin system in post-transplantation hypertension in patients with multiple kidneys. Linas, S.L., Miller, P.D., McDonald, K.M., Stables, D.P., Katz, F., Weil, R., Schrier, R.W. N. Engl. J. Med. (1978) [Pubmed]
  9. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. Streeten, D.H., Anderson, G.H., Freiberg, J.M., Dalakos, T.G. N. Engl. J. Med. (1975) [Pubmed]
  10. Lowering of hypertension by central saralasin in the absence of plasma renin. Phillips, M.I., Mann, J.F., Haebara, H., Hoffman, W.E., Dietz, R., Schelling, P., Ganten, D. Nature (1977) [Pubmed]
  11. Reactive hyperreninemia in renovascular hypertension after angiotensin blockage with saralasin or converting enzyme inhibitor. Case, D.B., Laragh, J.H. Ann. Intern. Med. (1979) [Pubmed]
  12. The antihypertensive effect of captopril. Evidence for an influence of kinins. Mimran, A., Targhetta, R., Laroche, B. Hypertension (1980) [Pubmed]
  13. Angiotensin II as a modulator of baroreceptor reflexes in the brainstem of conscious rats. Michelini, L.C., Bonagamba, L.G. Hypertension (1990) [Pubmed]
  14. Saralasin-induced renin release: its blockade by prostaglandin synthesis inhibitors in the conscious rat. Campbell, W.B., Jackson, E.K., Graham, R.M. Hypertension (1979) [Pubmed]
  15. Reciprocal relation between renin dependency and sodium dependency in essential hypertension. Gavras, H., Ribeiro, A.B., Gavras, I., Brunner, H.R. N. Engl. J. Med. (1976) [Pubmed]
  16. Angiotensin and thromboxane in the enhanced renal adrenergic nerve sensitivity of acute renal failure. Robinette, J.B., Conger, J.D. J. Clin. Invest. (1990) [Pubmed]
  17. The role of angiotensin in the intestinal vascular response to hypotension in a canine model. MacDonald, P.H., Dinda, P.K., Beck, I.T. Gastroenterology (1992) [Pubmed]
  18. Hemodynamic correlates of saralasin-induced arterial pressure changes. de Carvalho, J.G., Dunn, F.G., Kem, D.C., Chrysant, S.G., Froholich, E.D. Circulation (1978) [Pubmed]
  19. Glomerular and vascular atrial natriuretic factor receptors in saralasin-sensitive and -resistant two-kidney, one-clip hypertensive rats. Garcia, R., Gauquelin, G., Cantin, M., Schiffrin, E.L. Circ. Res. (1988) [Pubmed]
  20. Renin lowers blood-pressure. Gordon, D.B. Lancet (1978) [Pubmed]
  21. Saralasin infusion in the recognition of renovascular hypertension. Wilson, H.M., Wilson, J.P., Slaton, P.E., Foster, J.H., Liddle, G.W., Hollifield, J.W. Ann. Intern. Med. (1977) [Pubmed]
  22. Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors. Riegger, A.J., Lever, A.F., Millar, J.A., Morton, J.J., Slack, B. Lancet (1977) [Pubmed]
  23. Effect of saralasin in hypertensive patients on chronic hemodialysis. Lifschitz, M.D., Kirschenbaum, M.A., Rosenblatt, S.G., Gibney, R. Ann. Intern. Med. (1978) [Pubmed]
  24. Detection of renovascular hypertension with angiotensin II blockade. Baer, L., Parra-Carrilo, J.Z., Radichevich, I., Williams, G.S. Ann. Intern. Med. (1977) [Pubmed]
  25. Pressor response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects. Anderson, G.H., Streeten, D.H., Dalakos, T.G. Circ. Res. (1977) [Pubmed]
  26. Angiotensin II inhibits luteinizing hormone-stimulated cholesterol side chain cleavage expression and stimulates basic fibroblast growth factor expression in bovine luteal cells in primary culture. Stirling, D., Magness, R.R., Stone, R., Waterman, M.R., Simpson, E.R. J. Biol. Chem. (1990) [Pubmed]
  27. Characterization of angiotensin AT1A receptor isoform by its ligand binding signature. Chiu, A.T., Dunscomb, J.H., McCall, D.E., Benfield, P., Baubonis, W., Sauer, B. Regul. Pept. (1993) [Pubmed]
  28. Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1. Lim, K.T., Cosgrave, N., Hill, A.D., Young, L.S. Breast Cancer Res. (2006) [Pubmed]
  29. Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta. Brailoiu, E., Filipeanu, C.M., Tica, A., Toma, C.P., de Zeeuw, D., Nelemans, S.A. Br. J. Pharmacol. (1999) [Pubmed]
  30. Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor. Morton, J.J., Casals-Stenzel, J., Lever, A.F., Millar, J.A., Riegger, A.J., Tree, M. British journal of clinical pharmacology. (1979) [Pubmed]
  31. Anti-angiotensin antibodies cross-reactive with nonpeptide angiotensin antagonists as angiotensin receptor model. Dagenais, P., Escher, E. Regul. Pept. (1993) [Pubmed]
  32. Mechanism of preservation of glomerular perfusion and filtration during acute extracellular fluid volume depletion. Importance of intrarenal vasopressin-prostaglandin interaction for protecting kidneys from constrictor action of vasopressin. Yared, A., Kon, V., Ichikawa, I. J. Clin. Invest. (1985) [Pubmed]
  33. Saralasin bolus test. Rapid screening procedure for renin-mediated hypertension. Marks, L.S., Maxwell, M.H., Kaufman, J.J. Lancet (1975) [Pubmed]
  34. Sensitivity and specificity of screening tests for renal vascular hypertension. Grim, C.E., Luft, F.C., Weinberger, M.H., Grim, C.M. Ann. Intern. Med. (1979) [Pubmed]
WikiGenes - Universities